康希诺生物

Information Disclosure

Home >Investor Relations >Information Disclosure

H Share

VOLUNTARY ANNOUNCEMENT - INITIATION OF PHASE I/II CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT IN PHASE I CLINICAL TRIAL FOR RECOMBINANT POLIOMYELITIS VACCINE IN INDONESIA
VOLUNTARY ANNOUNCEMENT - INITIATION OF PHASE II/III CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT IN PHASE II CLINICAL TRIAL FOR TDCP ADOLESCENT AND ADULT
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF NEW DRUG APPLICATION FOR DTCP INFANT
INSIDE INFORMATION - CHANGE OF INTERESTS OF PARTIES ACTING IN CONCERT
Monthly Return of Equity Issuer on Movements in Securities
VOLUNTARY ANNOUNCEMENT - ANNOUNCEMENT ON THE 2024 INVESTOR OPEN DAY EVENT
VOLUNTARY ANNOUNCEMENT - ACCEPTANCE OF THE SUPPLEMENTAL DRUG APPLICATION FOR MENHYCIA
CHANGE OF EMPLOYEE REPRESENTATIVE SUPERVISOR
VOLUNTARY ANNOUNCEMENT INITIATION OF PHASE I CLINICAL TRIAL AND COMPLETION OF FIRST PATIENT ENROLLMENT FOR HAEMOPHILUS INFLUENZAE TYPE B CONJUGATE VACCINE, FREEZE-DRIED
Monthly Return of Equity Issuer on Movements in Securities

1 2 3 4 5 6 44